Blood supplies to be treated to reduce CJD riskBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7153.232a (Published 25 July 1998) Cite this as: BMJ 1998;317:232
- John Warden, parliamentary correspondent
Donated blood supplies in Britain are to be treated to reduce the risk of patients being infected with new variant Creutzfeldt-Jakob disease (CJD) because of a theoretical risk that it could be transmitted via the white blood cells.
The Department of Health is acting on the advice of its scientific advisers on the Spongiform Encephalopathy Advisory Committee (SEAC). As a precautionary measure, blood will go through a process of leucodepletion, which removes up to 95% of white blood cells. The process, which will cost £70m ($110m) …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial